27 results about "T cell subset" patented technology

The invention provides a dynamic regulation and control method for optimizing CAR-T cell amplification conditions, which comprises the following steps: acquiring high-frequency cell activity monitoring data from a cell culture system, and extracting metabolic marker fluctuation and proliferation rate mutation from the high-frequency cell activity monitoring data to obtain real-time cell state parameters; comparing the real-time cell state parameters with a T cell subset proportion and a cell factor release mode in historical immune data of the patient to obtain a cell state deviation value, and determining an abnormal fluctuation condition of proliferation rate mutation according to the cell state deviation value; if the abnormal fluctuation of the proliferation rate mutation exceeds a preset fluctuation threshold value, capturing proliferation signal abnormity by analyzing metabolic marker fluctuation and metabolic waste accumulation according to the cell state deviation value; according to the targeted culture parameter set, adjusting the oxygen supply quantity and the culture solution microenvironment of an oxygen concentration control system to obtain a culture environment for inhibiting cytokine storm and proliferation signal abnormity.

The invention discloses an application of TRBC2 in diagnosis of gout. According to the application, a recognized moving meniscus tearing patient (equivalent to a completely healthy synovial tissue) without gout medical history is taken as a contrast, single cell transcriptome analysis is carried out on the basis of a clinical biological sample, and a marker TRBC2 of a T cell subset is found to have significant difference in gout patients; a Raman spectrum technology is further adopted to find that the TRBC2 protein is specifically and highly expressed in synovial tissues of gouty arthritis patients and has relatively high diagnosis efficiency, and the TRBC2 is relatively high in clinical value and wide in application prospect when being used as a marker for diagnosing gout.

The invention discloses a method for predicting the curative effect of triple negative breast cancer immunotherapy by spatially quantizing CD39 + CD103 + CD8 + T cells, and relates to the technical field of biology.The method comprises the following specific steps that S1, an FFPE tumor tissue sample of a TNBC subject before immunotherapy is obtained, and a continuous section with the thickness of 3-5 microns is prepared and attached to a positive charge glass slide; s2, staining the section by using a combination containing CD8 / CD103 / CD39 / Pan-CK antibodies through a TSA sequential staining method, and then re-staining cell nucleuses by using DAPI; according to the method, spatial quantitative analysis is performed on a specific CD39 + CD103 + CD8 + T cell subset, a percentage index of target cells in CD8 + T cells and an average distance index of the target cells and nearest Pan-CK positive cells in a cancer nest region are set, and the target cells are determined according to comparison between the two indexes and a preset threshold value. According to the method, whether a subject is a potential benefit crowd treated by an anti-PD-1 / PD-L1 immune checkpoint inhibitor or not is accurately judged, a standardized technical means is provided for clinically screening the potential benefit crowd for immunotherapy, the accuracy and effectiveness of triple-negative breast cancer immunotherapy are effectively improved, and invalid treatment is reduced.

The invention discloses an application of a T cell subset in improving the treatment effect of AK112. The T cell subset is XCL1 + CCL3 + CD8 + T cells. The invention relates to an application of a specific T cell subset in improving the curative effect of AK112, a T cell agonist and AK112 are combined for use, and by synergistically activating the T cell function and reversing the immunosuppression microenvironment, the single drug resistance of AK112 is effectively overcome, the continuous remission time is remarkably prolonged, the treatment response is deepened, the applicable patient group is expanded, and meanwhile, the toxicity risk is reduced. The invention further develops a full-spectrum flow cytometry kit containing 13 antibodies, 13 key markers of the T cell subgroup can be simultaneously detected by one tube, patients sensitive to evoximab treatment (i.e., high expression of the subgroup) can be efficiently screened out, and a convenient tool is provided for accurate medication.

The invention discloses an identification kit and an identification system for a pathogenic T cell subset of IgA nephropathy, and belongs to the technical field of nephropathy detection.According to the identification kit, the identification of the pathogenic T cell subset in peripheral blood of the IgA nephropathy is realized by adopting a fluorescent dye labeled antibody combination, and the antibody combination comprises a CD4 fluorescent antibody, a CD103 fluorescent antibody and an ITGB1 fluorescent antibody. The antibody combination designed by the invention can detect a pathogenic T cell subset in peripheral blood of IgA nephropathy, the T cell subset is in negative correlation with a renal function index eGFR, is in positive correlation with severity of E lesion and T lesion in IgA nephropathy kidney pathological injury oxford typing, and can be used as a significant predictive factor for reduction of eGFR and severity of E lesion and T lesion. The method has an important guiding value for real-time monitoring and prognosis prediction of the IgAN, and opens up a new view for clinical management of the IgAN.

Provided herein are methods for manufacturing CAR-T cell products with high purity of TSCM subsets (>90%), independent of the variations from incoming leukapheresis. In some embodiments, to isolate the CCR7 and CD45RA double positive T cell subset, the processes described herein deplete CD45RO positive cells from leukapheresis and positively enrich for a CD4 and CD8 T cell population to isolation both TSCM and effector memory T cell (TEMRA) subsets, both of which positively express CD45RA and CCR7.

The invention provides an immune biomarker set for predicting the prognosis of a sepsis patient or evaluating the death risk of the sepsis patient and a corresponding reagent or kit thereof. The biomarker comprises a CD85j + T cell subset. The immune biomarker disclosed by the invention can also be combined with other indexes for application, and has very good effects of (a) predicting the prognosis of a sepsis patient; and / or (b) the effect of assessing the risk of death in sepsis patients.

The invention relates to an application of a CXCL13 + CD8 + T cell subset in preparation of a product for predicting prognosis of a melanoma patient, and the CXCL13 + CD8 + T cell subset is used as an analysis target to prepare a reagent for analyzing immune cell functions. Wherein the CXCL13 < + > CD8 < + > T cell subset refers to a CD8 < + > T cell subset capable of releasing a CXCL13 signal. Compared with the prior art, the research shows that by analyzing the expression level of effector molecules and immune checkpoint molecules in a tumor microenvironment and the density of a three-level lymph structure, the prognosis of a tumor patient can be more accurately predicted, and the reactivity of tumors to immunotherapy can be predicted; at present, a report for reflecting immune characteristics of melanoma by using the CXCL13 + CD8 + T cell subset as a biomarker is not found. The infiltration level of CXCL13 + CD8 + T cells in tumor tissues is quantitatively evaluated through flow cytometry, and more accurate and sensitive indexes are provided for prognosis evaluation of melanoma and liver cancer patients.

The invention relates to the technical field of biological pharmacy, and provides a double-target inhibition polypeptide or pharmaceutically acceptable salt and application thereof, the polypeptide comprises an amino acid sequence: TASPILYQMCCDYKR, and an amino acid fragment: X1WGIX2HSHFTHTX3WKX4 (I) with a structure as shown in a formula (I) is connected to the C tail end of the sequence. The polypeptide or the pharmaceutically acceptable salt thereof can generate high-affinity binding with PD-1 and CTLA-4 at the same time, has excellent biological blocking activity, can significantly improve the proportion of effector T cell subsets in tumor tissues, and effectively enhances the anti-tumor immune response of a body. Therefore, the polypeptide or the pharmaceutically acceptable salt thereof can be used for related detection of PD-1 and CTLA-4, can also be used as a novel anti-tumor candidate drug, and provides a brand new treatment scheme for cancer patients.

Some embodiments of the present disclosure provide a method for detecting immunity efficacy.SOLUTION: The method for detecting the effectiveness of immunity comprises: calculating the percentage of the number of each T cell subset in lymphocytes and the percentage of the number of each NK cell subset in lymphocytes to obtain a plurality of actual percentages of T cell subsets and a plurality of actual percentages of NK cell subsets; and determining whether the effectiveness of immunity is normal according to the actual percentages of T cell subsets and the actual percentages of NK cell subsets, so as to provide a more comprehensive test for the functions of various aspects of the immune system. Some embodiments of the present disclosure further provide use of a plurality of lymphocytes in the preparation of a pharmaceutical composition for treating a cancer in an individual, wherein the actual total number of T cells or the actual total number of natural killer cells is controlled within a theoretical range, thereby improving the efficacy of treating the cancer.SELECTED DRAWING: Figure 1

The present application relates to the technical field of medical diagnosis, in particular to a flow cytometry T cell subset detection automatic classification method based on machine learning, cell data of multiple blood samples is collected by using a flow cytometer, and a two-dimensional scatter plot is drawn; the cell population in the two-dimensional scatter plot is manually labeled, and the labeling result is mapped to high-dimensional data; the high-dimensional data is standardized to obtain high-dimensional space data; the high-dimensional space data is reduced in dimension based on a uniform manifold approximation and projection algorithm to obtain low-dimensional data; the low-dimensional data is density clustered based on a density-based spatial clustering algorithm, and the classification result is matched with the manual labeling; and the classification result is mapped back to the two-dimensional scatter plot for visual display, which overcomes the problems of strong subjectivity, low efficiency and poor reproducibility in the traditional manual classification method, and significantly improves the accuracy, efficiency and consistency of T cell subset classification.

The invention provides an ELISPOT (Enzyme-Linked Immunospot Assay) analysis method for detecting IFN-gamma and IL-2 secretion, which comprises the following steps: activating an ELISPOT plate, washing, adding IFN-gamma and IL-2 capture antibody coating with specific concentration, and staying overnight at 4 DEG C; recovering and counting target sample cells, resuspending the target sample cells according to a certain concentration, and adding the target sample cells into coated plate holes; incubating for more than 16 hours in an environment of 37 DEG C and 5% COC; washing the incubated plate, adding IFN-HRP and IL-2-ALP detection antibodies, and incubating at room temperature for 2 hours; after washing, adding a blue developing solution for developing for 10-15 minutes; adding a red developing solution, incubating for 10-15 minutes, and stopping developing; according to the method, T cell subset identification and multifunctional analysis can be carried out, in the early stage of vaccine research and development, due to the fact that target positive population is small, the number of obtained PBMC cells is small, two-factor detection can detect different cell factor reaction frequencies and locate different cell populations and subtypes at the same time, and comparison of two-factor data is beneficial to finding out population immune differences; and scientific research and vaccine development are promoted.

The invention provides a biomarker screening method and system for radiotherapy-immunity pneumonia prediction, and relates to the technical field of biomedicine. Aiming at the problem that the timeliness and the specificity of the existing radiotherapy-immunity pneumonia diagnosis cannot be considered at the same time, the method comprises the following steps: separating peripheral blood T cells of a radiotherapy-immunity pneumonia group and a control group, carrying out T cell clustering annotation in combination with single-cell secretory proteomics, an R language and an ImMen database, and screening a key T cell subset Tc17 by utilizing an Augur algorithm; the method comprises the following steps: determining pericytes as key interaction cells of Tc17 through cell interaction analysis, and screening a radiotherapy specific up-regulation gene MFAP4; and carrying out difference analysis on the Mfap4hi week cell subpopulation, and screening out a biomarker gene set containing 18 genes on the basis of an elastic network algorithm in combination with 3-fold nested cross validation. The invention provides a key basis for early prediction and accurate intervention of radiotherapy-immunity pneumonia, and has the advantages of high specificity and strong repeatability.

The invention discloses a biomarker combination for tuberculosis infection stage diagnosis and a detection method, the detection method specifically comprises the following steps: S1, sample collection and processing, S2, detection processing, S3, data processing, and S4, marker screening, and the invention relates to the technical field of clinical medical treatment. According to the biomarker combination for tuberculosis infection stage diagnosis and the detection method, ATB and HC and ATB and LTBI are distinguished through the core marker combination, AUC of LTBI and HC is larger than or equal to 0.875, AUC of multiple markers reaches 1.0, the diagnosis efficiency is remarkably superior to that of an existing TST and IGRAs method, diagnosis accuracy is higher, transition state metabolic characteristics of LTBI are defined, accurate division of different stages of tuberculosis infection is achieved, and the method is suitable for clinical application. According to the present invention, the problem that the core pain points of LTBI and ATB cannot be distinguished in the prior art is solved, the good staging specificity is provided, the immune correlation is good, and the basis is provided for the disease progression mechanism research and the treatment target screening by revealing the correlation between the metabolite and the CD4 < + > / CD8 < + > T cell subset.

This application discloses the application of a T cell subset in the preparation of a kit for evaluating B cell depletion therapy. The T cell subset includes CD4+. + T CM CD4 + T EM CD8 + T CM CD8 + T EM CD20 dim CD4 + T, CD20 dim CD8 + T, CD20 dim CD4 + T CM CD20 dim CD4 + T EM CD20 dim CD8 + T CM CD20 dim CD8 + T EM Th17.1, Th17, Th2, CD4 + T CM Th17.1, CD4 + T CM Th17, CD4 + T CM Th2, CD4 + T EM Th17.1, CD4 + T EM Th17 and CD4 + T EM The kit in this application assesses the depletion effect of B cells by using one or more of the Th2 cytoplasm types.

This invention relates to the field of biomedical technology, and in particular to mesenchymal stem cells, their preparation methods, and applications. The method for preparing mesenchymal stem cells includes the following steps: culturing the mesenchymal stem cells under hypoxic conditions with an oxygen volume fraction of 2%–4%, and during the hypoxic culture, pre-activating the mesenchymal stem cells by contacting them with an induction system containing 1–3 ng / mL Oncostatin M, 1–10 ng / mL IL-1β, and 2–10 ng / mL HMGB1 for 6–24 hours. Mesenchymal stem cells treated by this method can significantly inhibit lymphocyte proliferation, reduce the proportion of pro-inflammatory T cell subsets such as Th1 and Th17, increase the proportion of Treg cells, and effectively reduce the level of the inflammatory factor TNF-α.

The invention provides a flow type detection method for expression and activation of peripheral blood Vgamma9 T cells of machin, and belongs to the technical field of biological detection. The detection method provided by the invention can synchronously and specifically identify the T cells expressing the Vgamma9 in the peripheral blood of cynomolgus monkeys and the activated subsets of the T cells, and realizes accurate distinguishing and quantitative analysis of target cell populations. The method is clear in operation process and stable and reliable in result, and an effective tool is provided for evaluating the immune state of cynomolgus monkeys. Establishment of the method is helpful for efficiently monitoring the influence of drugs on specific T cell subgroups in preclinical drug safety evaluation and immune pharmacological research, and provides key technical support for research, development and evaluation of related biological agents.

The invention discloses a kit for early screening and auxiliary diagnosis of primary sicca syndrome and application of the kit. The invention discloses expression and functional characteristics of CD58, CD63 or CD147 in T cells, further discusses the relationship between the cells and pSS diseases as well as clinical significance and diagnostic value of the cells, and obtains a T cell subset with application value in early pSS diagnosis. According to the invention, the change of the CD58, CD63 or CD147 related T cell subsets in the peripheral blood of a newly attacked pSS patient is found for the first time, the clinical value of the CD58, CD63 or CD147 in the early diagnosis of pSS is disclosed, and the application has important significance on the diagnosis of the early pSS patient.

The invention relates to the field of atherosclerosis disease research, in particular to application of Tcf7hiCD8 + T cells in diagnosis or evaluation of atherosclerosis conditions. The Tcf7 is used as a core identification marker and is applied to an atherosclerosis environment, so that the Tcf7hiCD8 + T cell subset is successfully identified in the disease for the first time, the problem of missing detection caused by lack of key identification characteristics in the prior art is solved, and the cognitive blank in the field is filled.

This application relates to the field of biopharmaceutical technology, proposing a dual-target inhibitory peptide or a pharmaceutically acceptable salt thereof and its uses. The peptide comprises the amino acid sequence TASPILYQMCCDYKR, and an amino acid fragment of formula (I) is attached to the C-terminus of the sequence: X1WGIX2HSHFTHTX3WKX4 (I). The peptide or its pharmaceutically acceptable salt of this application can simultaneously bind with high affinity to PD-1 and CTLA-4, exhibiting excellent biological blocking activity. It can significantly increase the proportion of effector T cell subsets in tumor tissue, effectively enhancing the body's anti-tumor immune response. Therefore, the peptide or its pharmaceutically acceptable salt of this application can be used for the detection of PD-1 and CTLA-4, and can also serve as a novel anti-tumor drug candidate, providing a new treatment option for cancer patients.

This invention provides the application of JAK1 inhibitors in the preparation of drugs for treating adverse reactions related to immune checkpoint blockade. The CD8 inhibitor of this invention... + CTLs in T cells irAE Subgroups are key mediators of adverse reactions associated with multi-organ immunotherapy, specifically overexpressing JAK1 and activating the JAK-STAT signaling pathway, while anti-tumor CD8... + T cell subset 1 (CTL1) shows low JAK1 expression. Inhibitors specifically targeting JAK1 can block CTL expression. irAE‑Ⅱ Inhibiting the JAK-STAT pathway in subpopulations alleviates adverse reactions in multiple organs, including the heart and lungs, without affecting the anti-tumor CD8 inhibitors. + The anti-tumor function of T cell subsets can also enhance the efficacy of immune checkpoint inhibitors.

The application discloses a kit and a system for identifying a pathogenic T cell subpopulation of IgA nephropathy, and belongs to the technical field of kidney disease detection. The kit is used for identifying the pathogenic T cell subpopulation in peripheral blood of IgA nephropathy by using a combination of fluorescent dye-labeled antibodies. The antibody combination comprises CD4 fluorescent antibodies, CD103 fluorescent antibodies and ITGB1 fluorescent antibodies. The antibody combination designed by the application can detect a pathogenic T cell subpopulation in peripheral blood of IgA nephropathy. The T cell subpopulation is negatively correlated with a kidney function index eGFR, and is positively correlated with the severity of E lesions and T lesions in the oxford classification of kidney pathological damage of IgA nephropathy. The T cell subpopulation can be used as a significant predictor of the decrease of eGFR and the severity of E lesions and T lesions, has important guiding value for real-time monitoring and prognosis prediction of IgAN, and opens up a new field for clinical management of IgAN.

This invention discloses a novel CD8 + T cells and CD4 + T cell subsets. The CD8... + T cell subsets include: subsets characteristically expressing GZMK and PDCD1; subsets characteristically expressing GZMK, GPR183, IL7R, and ZNF683; subsets characteristically expressing GZMK and CXCL13; subsets characteristically expressing GZMK and ZNF683; and subsets expressing at least one of the following KIR genes: KIR2DL1, KIR2DL3, KIR2DL4, KIR3DL1, KIR3DL2, and KIR3DL3. The CD4+... + T cell subsets include: subsets that characteristically express FOXP3, TNFRSF9, and CTLA4; and subsets that characteristically express FOXP3 and BACH1.

The invention discloses a diagnostic marker detection system for an astrocyte IL-33 knockout EAE model, and relates to the technical field of in vitro diagnos.The diagnostic marker detection system comprises the steps that directional consistency constraint and four-domain prior weight and anchor point consistency scoring are built; selecting a minimum panel in four domains of inflammation chemotaxis, T cell subsets, myelin sheath axons and blood brain barriers, and generating a Th17 / Th1 and MMP9 / closed protein ratio and chemotaxis combination; standardized acquisition, platform alignment and bridging calibration are implemented, and intra-batch / inter-batch quality control and time window limitation are established; learning with monotone constraint and two-section calibration are executed, and animal-to-crowd domain adaptation is reserved; and outputting a star source index, double-threshold layering, longitudinal monitoring and an interpretable report, so that stable judgment and reproducibility improvement of cross-platform and cross-batch comparability, direction order-preserving, traceability and clinical bridging can be realized.

The invention belongs to the field of health food, and discloses a black tea and walnut peptide compound, a preparation method thereof and application of the black tea and walnut peptide compound in relieving immunosuppression induced by cyclophosphamide. Researches find that FT-WP treatment significantly reverses weight, thymus and spleen indexes of mice induced by cyclophosphamide, improves balance of jejunum CD4 + T cell subsets, and balances levels of cytokines and immune globulins. In addition, the research shows that FT-WP affects metabolic pathways such as metabolism of glycine, serine and threonine, metabolism of pyrimidine, digestion and absorption metabolism of protein and the like and regulation of metabolites such as choline, trimethylamine-N-oxide, prothioconazole, stearoyl carnitine, prostaglandin F2. Beta and the like. The black tea and walnut peptide composite food can relieve immunosuppression induced by cyclophosphamide and regulate abnormal serum metabolism.

The invention belongs to the field of preparation of genetically engineered drugs and antibody drugs, and relates to a bispecific single-chain antibody PC5-VB8 and application thereof in preparation of drugs for treating prostatic cancer. The bispecific single-chain antibody disclosed by the invention is shown as SEQ ID NO. 8. The bispecific single-chain antibody can specifically bind to tumor cells expressing PSCA, neutralize VEGF and block growth of endothelial cells and formation of endothelial tubes. In a prostatic cancer mouse model, the effect of inhibiting tumor growth is enhanced by combined treatment of the prostatic cancer vaccine and an engineered phage vaccine. The bispecific single-chain antibody not only can reduce the generation of tumor blood vessels, but also can significantly remodel the phenotype-function spectrum of tumor infiltration immune cells in combination with the engineered bacteriophage vaccine, NK cells and M1 macrophages are increased, MDSC cells are reduced, and the expression profiles of surface functional molecules of cDC, CD4 + and CD8 + T cell subsets significantly shift towards the anti-tumor direction.

This invention relates to the pharmaceutical field, specifically to a combination drug of trifluoperazine and a PD-1 inhibitor and its uses. This invention, through the combined use of trifluoperazine and a PD-1 inhibitor in the treatment of oral squamous cell carcinoma, has achieved superior efficacy compared to monotherapy. The combination of trifluoperazine and a PD-1 inhibitor in this invention increases CD8... + T cell expression levels and CD3 + CD8 + CD25 + Regarding the proportion of T cell subsets, it has a synergistic effect, providing a new strategy for the treatment of oral squamous cell carcinoma and showing great application prospects.